openPR Logo
Press release

Rapid Detection of Rheumatoid Arthritis / Early diagnosis is critical for treatment

12-18-2009 11:00 AM CET | Health & Medicine

Press release from: ORGENTEC Diagnostika

Rapid Detection of Rheumatoid Arthritis / Early diagnosis

Mainz, Germany – Rheumatoid arthritis, the most common chronic inflammatory disease of the joints, can now be more quickly and reliably detected.

This is made possible by a rapid test that can be used to check patients’ blood for antibodies against mutated citrullinated vimentin (Anti-MCV). If inflammation of the joints is present and MCV antibodies are found in the blood, it is very highly probable that rheumatoid arthritis is at the root of the symptoms. However, a negative test result does not exclude rheumatoid arthritis, because MCV antibodies are not detectable in all RA patients.

The advantage of the new technique: the rheumachec rapid test only takes 15 minutes. Previously, people suspected of having rheumatoid arthritis had to wait very long for a physical examination and test results. However, it is critical to get an early and precise diagnosis of rheumatoid diseases to aid in successful treatment.

Highly effective drugs have now become available, which can bring the disease to a standstill and reduce the threat of joint destruction. If the test result is positive, the patient should consult a rheumatologist or other specialist without delay.

In addition to the MCV antibody test, other laboratory tests may also indicate RA, for example the detection of rheumatoid factors or antibodies against cyclic citrullinated peptides (Anti-CCP). Previously, these tests were the most accurate means to identify a case of RA; however, these antibodies are only detectable in about two thirds of RA patients. Rheumatoid factors may also be found in healthy people, particularly as they age.

In Germany, about 800,000 people suffer from rheumatoid arthritis. The disease usually appears in people between 35 and 50 years of age, in midlife. If treatment is started too late, inability to work and disability threaten. RA is among the most costly diseases in all of medicine. In addition to the personal suffering and the enormous social burden, this disease generates immense costs for those afflicted, the health care system, and the entire economy.

More information at www.rheumachec.com and on http://www.youtube.com/watch?v=7SAxWY23jSU&feature=related.

Information for journalists:
Media background information at www.rheumachec.com. Images available upon request. We have up-to-date TV material available for television journalists.

About ORGENTEC Diagnostika:
Founded in 1988, ORGENTEC Diagnostika GmbH is a global market leader in the development, production, and distribution of test systems for autoimmune diagnostics. To date ORGENTEC has developed over 150 different test systems, of which many are protected by patents. These include detection techniques for the diagnosis and treatment monitoring for diseases in the rheumatic spectrum, vasculitis, diabetes, thromboses, and autoimmune diseases of the gastrointestinal tract. With our own distribution infrastructure in Germany, Austria, Switzerland, Hungary, and France, as well as an established network of partners, ORGENTEC products are used to benefit patients in over 80 countries around the world.
www.orgentec.com

ORGENTEC Diagnostika GmbH
Tobias Stolzenberg
Dr. Friederike Hammar
Carl-Zeiss-Straße 49
55129 Mainz, Germany
Tel. +49 6131 9258-677, -674
Fax +49 6131 9258-58
tobias.stolzenberg@orgentec.com
friederike.hammar@orgentec.com
www.orgentec.com
www.rheumachec.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rapid Detection of Rheumatoid Arthritis / Early diagnosis is critical for treatment here

News-ID: 112355 • Views: 1496

More Releases from ORGENTEC Diagnostika

Fully Automated Chlamydia Diagnostics from ORGENTEC
Mainz, June 19, 2012 – ORGENTEC Diagnostika (www.orgentec.com) has introduced six new tests for the diagnosis of infectious diseases. The new ELISA tests detect antibodies against Chlamydia trachomatis and Chlamydia pneumoniae. In addition, these test systems make it possible to differentiate between acute, latent, and chronic infection with these widespread bacterial pathogens. The new tests for the serological diagnosis of Chlamydia were developed specifically for Alegria®, ORGENTEC Diagnostika’s random access analyser.
Online Immunofluorescence Guide for Diagnosis of Autoimmune Diseases
Mainz, May 09 2012 – From now on the Immunofluorescence Guide for the Modern Autoimmunity Laboratory is available as a free ebook. The online reference work with numerous pictures of immunofluorescence patterns is accessible from the ORGENTEC Diagnostika website (www.orgentec.com) and from the website of the GRÜNE CLUB AUTOIMMUN (www.der-gruene-club.at). The online guide is public domain without login or registration. Whether it is the immunofluorescence pattern of antinuclear antibodies (ANA) on
Autoantibody Diagnostics in Autoimmune Liver Diseases
ORGENTEC Diagnostika (www.orgentec.com) has developed four new laboratory tests for the diagnosis of autoimmune liver diseases. These tests are now on the market. They are based on ELISA technology and were specifically developed for fully automated analysis with Alegria®. The new tests systems, called Anti-Sp100, Anti-gp210, Anti-LKM-1, and Anti-SLA, reliably detect specific autoantibodies that are characteristic of various autoimmune liver diseases. The tests thus also allow for reliable differentiation between these
A New Healthcare App: ORGENTEC Autoimmunity Guide
The ORGENTEC Autoimmunity Guide is now available for download from the Apple iTunes App Store and the Android Market. This app from Mainz-based ORGENTEC Diagnostika GmbH (www.orgentec.com) makes it possible to call up information about autoimmune diseases easily and comfortably from a smartphone or tablet – precisely, compactly, and without extensive searching. The ORGENTEC app offers comprehensive information about the diagnosis and monitoring of autoimmune diseases by means of antibody detection.

All 5 Releases


More Releases for Rheumatoid

How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis - New findings support research-based kit for management of Rheumatoid Arthritis Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively. Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data
Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Global Rheumatoid Arthritis Drug Market Outlook 2022
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi and Otezla) have dominated the overall anti-rheumatics market with
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the